摘要
目的对比恩替卡韦、替比夫定对乙肝肝硬化代偿期患者血清CAl25、CEA水平的影响。方法选择商丘市传染病医院2011年1月至2013年1月收治的50例乙肝肝硬化代偿期患者为研究对象,随机将其分为两组,每组25例,A组行恩替卡韦治疗,B组给予替比夫定治疗,比较两组患者治疗前后CAl25、CEA、肝功能水平及HBV-DNA水平。结果两组治疗前后白蛋白、门冬氯酸转氨酶、总胆红素比较差异均有统计学意义(P〈0.05),但组间比较差异未见统计学意义(P〉0.05)。两组治疗前后HBV-DNA、CAl25及CEA比较差异均有统计学意义(P〈0.05),但组间比较差异未见统计学意义(P〉0.05)。A组HBV-DNA阴转率为84%,B组为88%。结论恩替卡韦、替比夫定均能有效改善乙肝肝硬化代偿期患者肝功能及CAl25、CEA水平,HBV-DNA阴转率无明显差异。
Objective To compare the effects of entecavir and telbivudine on CA125, CEA lev- els of patients with hepatitis H cirrhosis at compensated phase. Methods Fifty patients with hepatitis B cirrhosis compensated period from January 2011 to January 2013 were selected as the research objects and randomly divided into group A and group B, with 25 cases in each group. Group A received entecavir treat- ment and group B received telbivudine treatment. CA125, CEA, liver function and HBV DNA levels, be- fore and after treatment of two groups were compared. Results ALB, AST, TBIL of the two groups before and after treatment were all significantly different (P 〈 0. 05 ), but the differences among groups were not significant (P 〉 0. 05). HBV - DNA, CA125 and CEA before and after treatment were all significantly dif- ferent (P 〈 0. 05), but the differences among groups were also not significant (P 〉 0. 05). The rate of se- roconversion of HBV-DNA in group A was 84% and 88% in group B. Conclusions Entecavir and telbi- vudine can effectively improve liver function in patients with hepatitis B in cirrhosis compensated period and the level of CA125 and CEA. The rate of HBV-DNA seroconversion has no significant difference.
出处
《中国实用医刊》
2015年第14期5-6,共2页
Chinese Journal of Practical Medicine
关键词
乙肝肝硬化代偿期
恩替卡韦
替比夫定
肿瘤标志物
Hepatitis B cirrhosis compensatory period
Entecavir
Telbivudine
Tumor markers